Neumora Therapeutics (NMRA) Income from Continuing Operations (2022 - 2026)
Neumora Therapeutics (NMRA) recorded quarterly Income from Continuing Operations of 53458000.0 in Q1 2026, up 10.08% quarter-over-quarter from 59450000.0 in Q4 2025, and up 21.38% on a YoY basis from 44043287.4 in Q1 2025.
Neumora Therapeutics (NMRA) Income from Continuing Operations (2022 - 2026) Analysis & Trends
Neumora Therapeutics' Income from Continuing Operations history runs 5 years deep, the most recent figure standing at 53458000.0 for Q1 2026.
- In Q1 2026, Income from Continuing Operations rose 21.38% year-over-year to 53458000.0; the TTM figure through Mar 2026 stood at 222394000.0 (up 13.82% YoY), while the FY2025 annual figure was 236928000.0, up 2.81% from the prior year.
- Income from Continuing Operations was 53458000.0 for Q1 2026 at Neumora Therapeutics, up from 59450000.0 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 28433000.0 in Q4 2022 to a low of 108462000.0 in Q4 2023.
- Historically, Income from Continuing Operations has averaged 55162200.0 across 5 years, with a median of 53721000.0 in 2024.
- The sharpest annual moves came in 2023 and 2024: Income from Continuing Operations plunged 281.47% in 2023, then jumped 45.77% in 2024.
- A 5-year view of Income from Continuing Operations shows it stood at 28433000.0 in 2022, then slumped by 281.47% to 108462000.0 in 2023, then surged by 45.77% to 58819000.0 in 2024, then declined by 1.07% to 59450000.0 in 2025, then rose by 10.08% to 53458000.0 in 2026.
- The last three Income from Continuing Operations figures came in at 53458000.0 (Q1 2026), 59450000.0 (Q4 2025), and 56755000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 814,307.08 Bn | 814,307.05 Bn | - | - |
| 2 | Belite Bio | 55,320.00 Bn | 55,320.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 17,149.72 Bn | 17,149.72 Bn | - | -2.97 Mn |
| 4 | Legend Biotech | 3,590.00 Bn | 3,589.71 Bn | 242.10 Mn | 30.80 Mn |
| 5 | Akari Therapeutics | 1,650.72 Bn | 1,650.72 Bn | - | -14.46 Mn |
| 6 | Evaxion A | 1,522.09 Bn | 1,522.07 Bn | - | -3.40 Mn |
| 7 | Psyence Biomedical | 229.39 Bn | 229.38 Bn | - | -1.50 Mn |
| 8 | Vertex Pharmaceuticals | 113.09 Bn | 105.85 Bn | 2.59 Bn | 1.03 Bn |
| 9 | Abivax | 90.15 Bn | 90.15 Bn | - | -56.48 Mn |
| 10 | Neumora Therapeutics | 320.17 Mn | 320.17 Mn | - | -53.46 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -53.46 Mn |
| Dec 31, 2025 | -59.45 Mn |
| Sep 30, 2025 | -56.76 Mn |
| Jun 30, 2025 | -52.73 Mn |
| Mar 31, 2025 | -67.99 Mn |
| Dec 31, 2024 | -58.82 Mn |
| Sep 30, 2024 | -72.55 Mn |
| Jun 30, 2024 | -58.70 Mn |
| Mar 31, 2024 | -53.72 Mn |
| Dec 31, 2023 | -108.46 Mn |
| Sep 30, 2023 | -53.03 Mn |
| Jun 30, 2023 | -38.54 Mn |
| Mar 31, 2023 | -35.60 Mn |
| Dec 31, 2022 | -28.43 Mn |
| Sep 30, 2022 | -29.20 Mn |